Ketotifen fumarate CAS NO.34580-14-8
Active Pharmaceutical Ingredients 2025-03-03
Catalog ID80017120
CAS NO.34580-14-8
Purity 96%
MDL NumberMFCD00079394
EINEC252-100-0
Molecular FormulaC19H19NOs.C4H4O4
Molecular Weight425.4974
| Aspect | Details |
|---|---|
| Chemical Structure | Ketotifen fumarate is a tricyclic antihistamine and mast cell stabilizer. Its chemical formula is C₂₀H₁₉NO₂·C₄H₄O₄, with a molecular weight of 389.41 g/mol. |
| Mechanism of Action | It acts as a selective histamine H₁ receptor antagonist, blocking the effects of histamine released during allergic reactions. Additionally, it stabilizes mast cells, preventing the release of inflammatory mediators such as histamine, leukotrienes, and prostaglandins. |
| Clinical Uses | Ketotifen fumarate is used for the treatment of allergic conditions, including allergic rhinitis, asthma, and allergic conjunctivitis. It is also used in the management of chronic urticaria and atopic dermatitis. |
| Formulations | Available as tablets, syrups, eye drops, and nasal sprays. It can also be formulated into extended-release tablets for once-daily dosing. |
| Storage Conditions | Store at room temperature (15–30°C) in a dry place, protected from light. |
| Side Effects | Common side effects include drowsiness, dry mouth, and gastrointestinal disturbances. Less common side effects may include headache, blurred vision, and weight gain. |
| Special Precautions | Use with caution in patients with liver or kidney impairment. Avoid driving or operating machinery if drowsiness occurs. |
| Regulatory Status | Approved for use in various countries for the treatment of allergic conditions. It is available over-the-counter in some regions |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
